Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23045125 | 1.00 | CHRM3 (0.42) | CHRM3TRPV1 | |
| SCHEMBL30308815 | 0.82 | TRPV1 (0.38) | TRPV1 | |
| SCHEMBL9455952 | 0.82 | TRPV1 (0.38) | TRPV1 | |
| SCHEMBL4813078 | 0.79 | CHRM3 (0.65) | CHRM3 | |
| SCHEMBL23045120 | 0.78 | DRD2 (0.50) | CHRM3TRPV1 | |
| SCHEMBL287422 | 0.78 | SLC18A3 (0.44) | CHRM3TRPV1 | |
| SCHEMBL205316 | 0.78 | SLC18A3 (0.44) | CHRM3TRPV1 | |
| SCHEMBL23045121 | 0.78 | TRPV1 (0.45) | CHRM3TRPV1 | |
| SCHEMBL23045126 | 0.78 | DRD2 (0.50) | CHRM3TRPV1 | |
| SCHEMBL23045122 | 0.78 | TRPV1 (0.45) | CHRM3TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250246-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-07 | — | — | US | disclosed |
| US-12286414-B2 | Method for producing heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-04-29 | — | — | US | disclosed |
| CN-118812481-A | Process for producing heterocyclylacetamide derivative | 持田制药株式会社 | 2024-10-22 | — | — | CN | disclosed |
| EP-4019485-B1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410989-A2 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-114206847-B | Process for producing heterocyclylacetamide derivative | 持田制药株式会社 | 2024-07-16 | — | — | CN | disclosed |
| EP-4019485-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019485-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| CN-114206847-A | Process for producing heterocyclylideneacetamide derivative | 持田制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| CN-113563209-A | Process for preparing optically active aminoalcohols | 持田制药株式会社 | 2021-10-29 | — | — | CN | disclosed |
| WO-2021039023-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | 持田製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
| EP-1368339-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12286414-B2 | Method for producing heterocyclidene acetamide derivative | COASY, NAAA, AADAC | CHRM3 4463/4885TRPV1 2623/4885 |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | MC1R, MC4R, MC5R | CHRM3 270/4885TRPV1 144/4885 |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | COASY, NAAA, AADAC | CHRM3 4463/4885TRPV1 2623/4885 |
| US-20250250246-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | COASY, NAAA, AADAC | CHRM3 4463/4885TRPV1 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.